Oxford Cancer Biomarkers (OCB) has gained a significant investment from leading South Korean healthcare company KwangDong Pharmaceutical Co. Ltd. (KDP). This investment marks an exciting new commercial phase for the Oxford university spin-out as the company translates innovative cancer biomarker…
30/May/19 Last Friday (May 24th) Dr Xu, our Chief Software Engineer, gave an academic report on “Diagnosis, Prognosis and Predicting Biomarkers of Cancers” at both the University of Chongqing and the Henan University of Science and Technology, which all the teachers and majority…
The following is a video that shows how OCB and Meridian IT worked together to extend the development of our Stage II bowel cancer risk stratification tool; ColoProg. It describes how OCB worked with Meridian IT to deploy IBM® PowerAI Vision running on…
14th March 2019. OCB is proud to announce that an article on challenges and solutions in patient treatment strategies for stage II colon cancer has been published in Gastroenterology Report. The publication reviews the options for measuring biomarkers associated with…
Press release: Oxford Cancer Biomarkers – 13th February 2019 OCB has been working with Meridian IT UK on combining leading edge diagnostics with AI technology to improve outcomes for cancer patients. We are delighted to announce that Meridian IT UK…
Press Release Oxford Cancer Biomarkers, Tuesday 6th November 2018. OCB is pleased to announce that it is an SME partner to University Hospital Coventry and Warwickshire NHS Trust’s successful bid for the PathLAKE project. Greg Clark, UK Secretary of State…
We are pleased to welcome Julie Simpson to our small but growing team at OCB as our new Sales and Business Development Manager. Julie has extensive experience from 21 years commercial work in both pharmaceuticals and medical devices; in various…
We are pleased to announce the launch of Oxford Cancer Biomarkers’ newly designed website www.oxfordbio.com. In redesigning our site, our goal is to provide a user-friendly browsing experience, in which to learn about our pioneering cancer biomarker technologies. We will…
Oxford Cancer Biomarkers launches ToxNav to improve morbidity and mortality rates in patients undergoing CRC chemotherapy Oxford, UK, 28 June 2018: Oxford Cancer Biomarkers Limited (www.oxfordbio.com) has announced the launch of ToxNav – a genomic test to identify cancer patients…
ESMO World Congress on Gastrointestinal Cancer Barcelona, Spain 20-23 Jun 2018 At ESMO-GI on 22nd June 2018 OCB was pleased to display the poster showing the clinical utility of ToxNav in predicting the most serious capecitabine-related toxicities. The data also…